Suppression of circadian secretion of glucagon-like peptide-1 by the saturated fatty acid, palmitate

被引:39
作者
Martchenko, A. [1 ]
Oh, R. H. [1 ]
Wheeler, S. E. [1 ]
Gurges, P. [1 ]
Chalmers, J. A. [1 ]
Brubaker, P. L. [1 ,2 ]
机构
[1] Univ Toronto, Dept Physiol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
Bmal1; exocytosis; GLP-1; mitochondrial metabolism; Nampt; DIET-INDUCED OBESITY; INSULIN-SECRETION; GENE-EXPRESSION; CLOCK GENES; METABOLISM; RHYTHMS; STRESS; CYCLE; BMAL1; GLP-1;
D O I
10.1111/apha.13007
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
AimGlucagon-like peptide-1 is an incretin hormone secreted by the intestinal L-cell with a circadian rhythm that parallels expression of the core clock gene, Bmal1. Although feeding rats a high-fat/high-sucrose Western diet impairs rhythmic glucagon-like peptide-1 release, the mechanisms underlying this effect remain unclear. Therefore, the aim of this study was to determine the pathway(s) by which the saturated fat, palmitate, a major component of the Western diet, impairs circadian glucagon-like peptide-1 secretion. MethodsMurine mGLUTag L-cells were synchronized, and the effects of palmitate pre-treatment on gene expression and glucagon-like peptide-1 secretion were determined, in addition to metabolite quantification, mitochondrial function analysis and enzyme inhibition and activation assays. Glucagon-like peptide-1 secretion was also analysed in ileal crypt cultures from control and Bmal1 knockout mice. ResultsPre-treatment with palmitate dampened Bmal1 mRNA and protein expression and glucagon-like peptide-1 secretion at 8 but not 20 hours after cell synchronization (P < .05-.001). Glucagon-like peptide-1 release was also impaired in Bmal1 knockout cultures as compared to wild-type controls (P < .001). Palmitate pre-treatment reduced expression of the Bmal1 downstream target, nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in the synthesis of NAD(+). This was paralleled by dampening of total NAD(+) levels, as well as impaired mitochondrial function and ATP production (P < .05-.001). Whereas direct inhibition of nicotinamide phosphoribosyltransferase also decreased glucagon-like peptide-1 release, activation of this enzyme restored glucagon-like peptide-1 secretion in the presence of palmitate. ConclusionPalmitate impairs L-cell clock function at the peak of Bmal1 gene expression, thereby impairing mitochondrial function and ultimately rhythmic glucagon-like peptide-1 secretion.
引用
收藏
页数:12
相关论文
共 50 条
[31]   Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides [J].
Liu, Can ;
Zhang, Mian ;
Hu, Meng-yue ;
Guo, Hai-fang ;
Li, Jia ;
Yu, Yun-li ;
Jin, Shi ;
Wang, Xin-ting ;
Liu, Li ;
Liu, Xiao-dong .
JOURNAL OF ENDOCRINOLOGY, 2013, 217 (02) :185-196
[32]   Abscisic Acid Stimulates Glucagon-Like Peptide-1 Secretion from L-Cells and Its Oral Administration Increases Plasma Glucagon-Like Peptide-1 Levels in Rats [J].
Bruzzone, Santina ;
Magnone, Mirko ;
Mannino, Elena ;
Sociali, Giovanna ;
Sturla, Laura ;
Fresia, Chiara ;
Booz, Valeria ;
Emionite, Laura ;
De Flora, Antonio ;
Zocchi, Elena .
PLOS ONE, 2015, 10 (10)
[33]   Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion [J].
Parker, H. E. ;
Wallis, K. ;
le Roux, C. W. ;
Wong, K. Y. ;
Reimann, F. ;
Gribble, F. M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (02) :414-423
[34]   Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes [J].
De Block, Christophe E. M. ;
Dirinck, Eveline ;
Verhaegen, Ann ;
Van Gaal, Luc F. .
DIABETES OBESITY & METABOLISM, 2022, 24 (05) :788-805
[35]   Essential Role of Syntaxin-Binding Protein-1 in the Regulation of Glucagon-Like Peptide-1 Secretion [J].
Campbell, Jhenielle R. ;
Martchenko, Alexandre ;
Sweeney, Maegan E. ;
Maalouf, Michael F. ;
Psichas, Arianna ;
Gribble, Fiona M. ;
Reimann, Frank ;
Brubaker, Patricia L. .
ENDOCRINOLOGY, 2020, 161 (05)
[36]   Why is it so difficult to measure glucagon-like peptide-1 in a mouse? [J].
Windelov, Johanne A. ;
Albrechtsen, Nicolai J. Wewer ;
Kuhre, Rune E. ;
Jepsen, Sara L. ;
Hornburg, Daniel ;
Pedersen, Jens ;
Jensen, Elisa P. ;
Galsgaard, Katrine D. ;
Winther-Sorensen, Marie ;
Orgaard, Anne ;
Deacon, Carolyn F. ;
Mann, Matthias ;
Kissow, Hannelouise ;
Hartmann, Bolette ;
Holst, Jens J. .
DIABETOLOGIA, 2017, 60 (10) :2066-2075
[37]   Glucagon-like peptide-1, a matter of taste? [J].
Jensterle, Mojca ;
DeVries, J. Hans ;
Battelino, Tadej ;
Battelino, Saba ;
Yildiz, Bulent ;
Janez, Andrej .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2021, 22 (04) :763-775
[38]   Glucagon-Like Peptide-1 Gene Therapy [J].
Rowzee, Anne M. ;
Cawley, Niamh X. ;
Chiorini, John A. ;
Di Pasquale, Giovanni .
EXPERIMENTAL DIABETES RESEARCH, 2011,
[39]   Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans [J].
Wu, T. ;
Bound, M. J. ;
Standfield, S. D. ;
Gedulin, B. ;
Jones, K. L. ;
Horowitz, M. ;
Rayner, C. K. .
DIABETES OBESITY & METABOLISM, 2013, 15 (05) :474-477
[40]   Glucagon-like peptide-1 and islet lipolysis [J].
Winzell, MS ;
Ahrén, B .
HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) :795-803